【摘要】 目的 探讨在不同造模时间、给药时间和剂量下黄芩苷镁对非酒精性脂肪性肝炎(NASH)大鼠模型的治疗效果。方法 采用高脂饮食诱导法建立NASH大鼠模型，将Sprague-Dawley(SD)大鼠随机分为6组，分别为空白组(16只)、模型组(16只)、黄芩苷镁1～4组(剂量分别为25、50、100、150 mg/kg,各8只)。尾静脉注射给药，观察造模时间、给药时间和剂量对大鼠的体重相关指标(体重、肝湿重、肝指数)、血清生化指标及病理结果的影响。结果 造模6周时，模型组大鼠体重相关指标均较空白组增加，差异均有统计学意义(P<0.05),2组大鼠血清生化各指标均无显著变化，差异均无统计学意义(P>0.05);造模8周时，与空白组比较，模型组大鼠体重、肝湿重、肝指数、血清谷草转氨酶(AST)、谷丙转氨酶(ALT)、总胆固醇(TC)、甘油三酯(TG)和低密度脂蛋白(LCL-C)水平及非酒精性脂肪性肝病活动度积分(NAS)显著增加，高密度脂蛋白(HDL-C)水平显著降低，差异均有统计学意义(P<0.05)。给药1周时，黄芩苷镁1～4组体重相关指标均无显著变化，差异均无统计学意义(P>0.05),与模型组比较，黄芩苷镁3组大鼠血清ALT、LDL-C水平下降，差异有统计学意义(P<0.05),AST、TC、TG水平下降，HDL-C水平升高，但差异均无统计学意义(P>0.05);黄芩苷镁4组大鼠血清TG和LDL-C水平降低，HDL-C水平升高，差异有统计学意义(P<0.05)。给药2周时，与模型组比较，黄芩苷镁2组大鼠肝湿重及ALT、AST、TC、TG水平及NAS均显著降低，差异均有统计学意义(P<0.05),黄芩苷镁3组、黄芩苷镁4组大鼠体重、肝湿重、肝指数，以及ALT、AST、TC、TG、LDL-C水平及NAS明显降低，HDL-C水平明显升高，差异均有统计学意义(P<0.05)。结论 造模8周比6周更接近于NASH模型，150 mg/kg的黄芩苷镁给药2周对NASH大鼠的治疗效果较好，且其作用具有剂量依赖性。更多还原

【Abstract】 Objective To explore the therapeutic effects of baicalin magnesium on non-alcoholic steatohepatitis(NASH) rats at different modeling time, administration time and doses.Methods NASH rat models were established by the method of high-fat diet induction.Sprague-Dawley(SD) rats were randomly divided into six groups: the blank group(16 rats),the model group(16 rats) and the baicalin magnesium 1-4 groups(eight rats in each group at the doses of 25,50,100 and 150 mg/kg, respectively).The medicine was injected into caudal vein of the rats to investigate the effects of modeling time, administration time and doses on body weight related indexes(body weight, wet weight of liver, liver index),serum biochemical indexes and pathological results.Results At six weeks, compared with the blank group, the weight related indexes of rats in the model group were increased, and the difference was statistically significant(P<0.05).There were no significant changes in serum biochemical indexes of rats between two groups(P>0.05).At eight weeks, compared with the blank group, the liver index, aspartate aminotransferase(AST),alanine aminotransferase(ALT),total cholesterol(TC),triglyceride(TG),low density lipoprotein(LCL-C) in serum and non-alcoholic fatty liver disease activity score(NAS) of the model group were significantly increased, while high density lipoprotein(HDL-C) was significantly decreased, and the differences were statistically significant(P<0.05).After one week of administration, there were no significant differences in the weight related indexes of baicalin magnesium 1-4 groups(P>0.05).Compared with the model group, the levels of ALT and LDL-C in serum of rats in baicalin magnesium 3 group decreased, and the differences were statistically significant(P<0.05),the levels of AST,TC,TG decreased, HDL-C levels increased, but the difference was not statistically significant(P>0.05).The levels of ALT,AST,TC,TG and LDL-C in serum of rats in baicalin magnesium 4 group decreased, while the levels of HDL-C increased, with statistical significance(P<0.05).After two weeks of administration, compared with the model group, there were significant decreased in the wet weight of liver, ALT,AST,TC,TG and NAS in the baicalin magnesium 2 group, the differences were statistically significant(P<0.05).And the body weight, wet weight of liver, liver index, ALT,AST,TC,TG,LDL-C and NAS in the baicalin magnesium 3 group and baicalin magnesium 4 group were significantly decreased, while HDL-C was significantly increased, and the differences were statistically significant(P<0.05).Conclusion The rat model at eight weeks is more similar to the NASH model than six weeks.The therapeutic effect of 150 mg/kg baicalin magnesium on NASH rats is better at two weeks, and its effect is dose-dependent.更多还原